High-intensity Resistance Training in Post-exacerbation COPD

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorIstituti Clinici Scientifici Maugeri SpA

About this trial

After a COPD exacerbation, many individuals experience severe weakness in the leg muscles, especially the quadriceps. This weakness can make daily activities difficult and slow down recovery. Traditional respiratory rehabilitation usually focuses on endurance training, which is effective but often hard to tolerate soon after an exacerbation due to persistent symptoms and limited functional capacity.

This study aims to compare two early rehabilitation approaches during recovery from a COPD exacerbation: a maximal strength training (MST) programme using high loads and few repetitions, and a traditional endurance-based training programme.

The investigators aim to determine whether MST is easier to tolerate, especially in terms of breathlessness, and whether MST can improve muscle strength, efficiency, and overall exercise tolerance as well as or better than endurance training.

The results will help identify the most suitable rehabilitation strategy for individuals recovering from a COPD exacerbation, particularly for those who struggle with high-intensity endurance exercise.

Eligibility criteria

Qualifiers

COPD diagnosis according to the GOLD guidelines [11] with FEV1/FVC <70%

Stable clinical condition (pH>7.30) [11]

Hospital discharge within 3 weeks from an event of hospitalization due to an acute exacerbation of COPD.

Absence of significant motor disability, described by the possibility of performing the 6MWT.

Disqualifiers

Presence of lung diseases other than COPD

Orthopedic and neurological conditions that prevent the execution of functional tests

Severe neurological and cardiologic comorbidities or other severe diseases compromise exercise tolerance.

Cognitive impairment evaluated by Mini-Mental State Examination (MMSE) score as < 25.

Trial design

Treatments tested in this trial

  • HIRT
  • HIET

Treatment groups

64 Participants
are divided into 2 treatment groups

Sponsors and collaborators